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The patterns of a woman’s normal ovarian activity can take many forms from childhood to
menopause. These patterns lie on a continuum ranging from no ovarian activity to a fully
fertile ovulatory cycle, but among the other defined patterns are cycles with anovulatory
ovarian activity, including luteinized unruptured follicles (LUFs), and ovulatory cycles with
deficient or short luteal phases. For any woman, these patterns can occur in any order,
and one can merge into the next, without an intervening bleed, or be missed entirely.
Consequently, it is not yet possible to predict the pattern of a future cycle, but it is
possible to use our knowledge of the continuum to interpret the current cycle, which has
clear implications for the management of personal fertility. An individual’s position in the
continuum can be monitored directly in real time by daily monitoring of ovarian hormone
excretion rates, without either calendar-type calculations or reference to population
means and standard deviations. The excretion of urinary estrone glucuronide (E1G) gives
a direct measure of follicular growth, and the post-ovulatory rise in urinary pregnanediol
glucuronide (PdG) following an E1G peak provides good evidence of ovulation. Specific
values of the PdG excretion rate can be used to determine whether a cycle is anovulatory
with or without a LUF, or is ovulatory and infertile or ovulatory and fertile. These specific
values are important signposts for navigating the continuum. For a woman to take
advantage of the knowledge of the continuum, the data must be reliable, and their
interpretation has to be based on the underlying science and provided in an appropriate
form. We discuss the various factors involved in acquiring and providing such information
to enable each woman to navigate her own reproductive life.
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INTRODUCTION
The achievement of pregnancy requires the precise integration of physiological, biochemical, and
anatomical events of a woman’s menstrual cycle. These events can bemonitored using daily cervical
mucus characteristics, the basal body temperature (BBT) and ovarian steroid levels, among other
measurements. Observations made each day during the menstrual cycle can be used to generate a
profile for an individual woman. When interpreted appropriately, this profile provides a woman
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with useful information about the events and their timing, and
her current fertility status. However, even consecutive cycles from
the same woman can vary considerably from month to month.
This cycle variation lies within a continuum (1) ranging from an
anovular cycle, which happens when one or more of the steps
occur(s) inappropriately, to a fertile cycle, which only happens
when all the steps occur appropriately within tolerance.
Changes in the levels of the ovarian steroids are directly
related to the underlying ovarian physiology because these
compounds emanate from the ovary (2). The growth of a follicle
is related unambiguously to the rate of secretion of estradiol
from the follicle, and ovulation and corpus luteum formation
are indicated unambiguously by rising progesterone levels.
The corollary of this is that both estrogens and progesterone,
or their urinary metabolites estrone-3-glucuronide (E1G), and
pregnanediol-3-glucuronide (PdG), respectively, have to be
monitored if the cycle is to be understood. All other markers are
indirect, in which case they are nonlinearly dependent on the
levels of the ovarian steroids and can only be used to infer that
specific eventsmight follow.
If ovarian steroids, or their urinary metabolites, are to be used
to monitor the menstrual cycle, at least four criteria have to be
fulfilled. First, it must be established that changes in the levels
of the steroids are quantitatively or semi-quantitatively related to
physiologically significant events. In this case, a woman’sminimal
requirement is that ovulation and the bounds of the fertile
period are reliably identified. Quite reasonably, many women
have higher aspirations than this and the continuum provides
the basis for such a higher order understanding of the cycle.
Second, the assay technique used to monitor the analytes must
be shown to be specific, accurate and precise. For an assay to
be useful it must measure only the analyte of interest and it
must do so with suitable sensitivity and a suitable working range.
Third, unless 24-h urine samples are employed, it is necessary to
account for the inevitable natural fluctuations in both the total
volume of urine in a sample and the time between voids (rate
of urine volume production). Fourth, the data obtained during
the menstrual cycle have to be interpreted in a coherent fashion.
This is especially important because the E1G and PdG profiles
of apparently “normally cycling” women can change from one
cycle to the next. For a woman monitoring her own fertility, this
means that her own data for the current cycle, not an average
of her own or other womens’ cycles, have to be interpreted. The
continuum, as defined by Brown (1), provides a rational basis
for interpreting each individual cycle, but its use depends on a
complete understanding of the physiology, reliable assays for the
ovarian steroids, and correction for the urine production rate.
Our purpose is to provide clinicians with data and reference
material to enhance their understanding of the continuum. We
have developed guidelines based on many years of experience
with measurements of ovarian steroid excretion rates during
individual menstrual cycles. Our focus is on monitoring
individual cycles in real time. We stress the importance of
correcting for urine production rate to do this and demonstrate
that such a correction allows the use of universal excretion rate
thresholds for pregnanediol (or its glucuronide) in providing
signposts to guide passage through the continuum. In doing
so we define the various deficient cycle patterns in a clinically
practical manner. The understanding of the continuum, and
what is required to navigate it, is of fundamental importance for
managing infertility.
DEMONSTRATING THE RELEVANCE OF
QUANTITATIVE MEASUREMENT OF
ANALYTES AS FERTILITY MARKERS
To establish that measurements of a biomarker are quantitatively
or semi-quantitatively related to physiologically significant
events is not a simple matter. The first requirement is to establish
that the analyte reflects only the physiology of interest. Then
it is essential to show that the test is not confounded by
extraneous factors such as measurement errors, matrix effects,
concentration effects, the (bio-)chemistry of the test or other
non-specific effects. Given this, it takes a considerable amount of
work to establish that the test is measuring the marker of choice
accurately and the underlying activity of the organ correctly.
This was first achieved for ovarian estrogens in the 1950s
when a chemical method was developed (3, 4). This assay
measured the sum of hydrolysed metabolites of ovarian estradiol
excreted in urine (5). Using methods such as isotopic dilution
it was established that the assay measured only the urinary
metabolites of ovarian estradiol, and that the excretion rate
of the sum of estrone, estradiol, and the estriol metabolites is
directly related to the ovarian production rate of estradiol (6).
It is well established that follicular growth is related to the
ovarian estradiol production rate and the urinary excretion rate
of estrogens (or E1G) (7–11). An assay for urinary pregnanediol
(Pd), a metabolite of progesterone produced in this assay by
hydrolysing PdG, was established with similar care (12). It is
important to note that both of these assays were applied to 24-
h urine collections and the result was expressed as an amount [in
micrograms (µg)] per 24 h which is the rate of excretion of the
steroid. This is independent of the volume of urine into which
the steroid is excreted.
CHARACTERIZING THE CONTINUUM
Work carried out over many years with careful analysis of
many individual cycles, including pregnancy cycles, resulted
in the concept of the continuum by Brown (1). This concept
arose from finding that there was a progression from anovular
activity of childhood, through the establishment of cycling to
fully fertile ovular cycles during adolescence and then back
again as a woman approached the menopause. These same
stages were observed during years of monitoring gonadotrophin
therapy at the Royal Women’s Hospital in Melbourne during
the 1970s and 1980s (13–15). Based on a detailed experimental
model (13), each of these cycles could be understood as
normal responses to a woman’s life and her physiological state.
In these cases the hormonal cycle patterns were compared
with (i) laparoscopy and ultrasound which show ovulation
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directly, and (ii) endometrial biopsy which distinguishes between
estrogenic and progestogenic control of the development of the
endometrium.
The continuum was recognized and defined in terms of the
urinary excretion rates of (i) pregnanediol (Pd) or its glucuronide
(PdG) and (ii) total estrogens (TE) or estrone glucuronide (E1G).
As the parent compounds, progesterone and estradiol, emanate
directly from the ovary, unlike luteinising hormone (LH), follicle
stimulating hormone (FSH) and the other measures often used
to monitor the cycle, Pd(G), TE, and E1G provide a direct link
with the events in the ovary (2). The excretion rates of these
steroids change characteristically during the menstrual cycle and
specific hormonal patterns are associated with particular cycle
types.
The key PdG excretion rates are thresholds that generally
are exceeded if particular menstrual cycle events have occurred.
While it does not really matter whether serum hormones,
urinary PdG and E1G or urinary Pd and TE are considered, the
thresholds differ and it matters greatly that the serum values
are concentrations whereas the urinary values are excretion
rates. Experience indicates that the excretion rate of PdG will
exceed 13.5 µmol/24 h within 6 days of the estrogen peak
day in the luteal phase of a fertile, conceptual (and therefore
ovulatory) cycle (1). In an anovulatory cycle, the excretion rate
of PdG will not exceed 7 µmol/24 h (16). Between these two
thresholds lies a third [9 µmol/24 h (16)] that is biochemical
proof of ovulation and hence can be used to distinguish a
luteinized unruptured follicle (LUF) from an inadequate luteal
phase.
A LUF is a follicle that has been luteinized and has either failed
to rupture or has ruptured in such a way that the ovum is not
released (17). Given this definition, diagnosis is best made on
the basis of ultrasound, although LUFs were originally described
based on laparoscopy (18). However, LUFs are also associated
with lower (19–22) or more slowly rising (23) progesterone (or
Pd or PdG) levels, although there are some exceptions (24).
Based on this, we employ a hormonal definition of a LUF
based on the threshold PdG excretion rate of 9 µmol/24 h
PdG (which is equivalent to the original 2 mg/24 h Pd), as has
been accepted for decades, is biochemical proof of ovulation
(16). It follows that lower values indicate that ovulation has
not occurred. However, the fact that progesterone levels rise
above the follicular phase baseline means that some luteinization
must have occurred. From a biochemical point of view this
is a LUF.
These thresholds have been confirmed over many years by
over a million assays and the associated clinical observations
obtained during the study of thousands of individual cycles.
The only way to demonstrate definitively that a cycle is fertile
is that it ends in pregnancy, but it can not be concluded that
a cycle is infertile just because it does not. Nevertheless, the
threshold we take to indicate fertility (a value in excess of
13.5 µmol/24 h PdG within 6 days of the estrogen peak day)
can be examined by taking pregnancy as a proxy for a fertile
cycle. Our own data from 213 cycles yield acceptable estimates
of the sensitivity (1.00 [95% CI: 0.93, 1.00]), specificity (0.35
[95% CI: 0.28, 0.43]), positive predictive value (PPV, 0.32 [95%
CI: 0.30, 0.35]), and negative predictive value (NPV, 1.00) of
the threshold. We emphasize that the low specificity and PPV
are to be expected because not every potentially fertile cycle
results in pregnancy, whereas, the high sensitivity and NPV
merely reflect the fact that no pregnancies resulted from those
cycles in which the threshold was not exceeded throughout
the 6 days following the estrogen peak day. Some further
substantiation of the reliability of this threshold can be obtained
from the data of Brown et al. (15) who used a slightly lower
threshold (equivalent to about 11.2 µmol/24 h PdG). Despite
this, their 444 cycles yielded very similar values of the sensitivity
(0.94 [95% CI: 0.86, 0.98]), specificity (0.52 [95% CI: 0.47,
0.58]), PPV (0.31 [95% CI: 0.29, 0.34]), and NPV (0.97 [95%
CI: 0.94, 0.99]). The most significant difference between these
two analyses is that there were five pregnancies using the
lower threshold, but no pregnancies when it increased to 13.5
µmol/24 h PdG.
The lowest threshold (the equivalent of 7 µmol/24 h PdG)
is widely accepted as a marker for the end of the fertile period
[(1, 25–28)]. Similarly, the middle threshold (the equivalent
of 9 µmol/24 h PdG) is also widely accepted as biochemical
evidence of ovulation [(16, 29–31)]. Nevertheless, we accept
that there are few reports in which these two urinary Pd or
PdG excretion rate thresholds have been considered using either
laparoscopy or ultrasound (32). There is further work to be
done.
Nevertheless, the substantial body of work that has been done
has yielded the following definitions of distinct cycle types (where
the luteal phase is defined as the day after the E1G peak day to the
last day of the cycle inclusive):
A) A fertile cycle has a luteal phase length of 11–17 days and the
PdG excretion rates exceed 13.5 µmol/24 h within 6 days of
the E1G peak (Figure 1A).
B) Anovulatory cycles
i In the absence of any follicular growth at all there is no
significant systematic change in the E1G or PdG excretion
rates (Figure 1B).
ii The E1G excretion rate rises and falls (fluctuates), but
the PdG excretion rates do not exceed 7 µmol/24 h
(Figure 1C).
iii The E1G excretion rate rises but then stays constant for a
period of time and the PdG excretion rates do not exceed
7 µmol/24 h (first 28 days of Figure 1D).
Anovular cycles can occur in young, lactating and
perimenopausal women, elite athletes and any woman
experiencing stress. Such cycles are usually sporadic, but are
sometimes more frequent.
C) Ovulatory or anovulatory cycles in which the E1G excretion
rate rises and falls and there are various PdG excretion
rates.
i luteinized unruptured follicle (LUF) cycles show an E1G
peak followed by an increase in PdG excretion rates that
may exceed 7 µmol/24 h, but do not exceed 9 µmol/24 h
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FIGURE 1 | Examples of E1G (◦) and PdG (•) excretion rates for an ovulatory, fertile cycle, and three anovulatory cycle subtypes. The PdG thresholds 7, 9, and 13.5
µmol/24 h are shown as broken horizontal lines. (A) A normal cycle where the E1G excretion rates fluctuate and the PdG excretion rates exceed all 3 thresholds and
the luteal phase length is 14 days. The vertical line is the day of the LH peak. (B) An anovular cycle where the E1G excretion rates are consistently low as are the PdG
excretion rates. (C) An anovular cycle where the E1G excretion rates fluctuate but the PdG excretion rates do not exceed 7 µmol/24 h. (D) This cycle has a long
anovulatory phase of 28 days where the E1G excretion rates stay effectively constant as do the PdG excretion rates. This was followed by an ovulation, but as the
PdG excretion rates did not exceed the 13.5 µmol/24 h threshold the cycle had a deficient luteal phase. Data in this and subsequent figures are derived from (i) the
UNDP/UNFPA/WHO/World Bank study on the Hormonal Definition of the Fertile Days of the Cycle by Home Monitoring for Natural Family Planning, protocol #90905
(Ovarian Monitor); (ii) the Fertility Urinary Monitoring Study, approved by the Northern B Health and Disability Ethics Committee, New Zealand, # 12/NTB/18 (collected
using the MICT superparamagnetic particle assay); (iii) the Women’s Fertility Study, approved by the Central Health and Disability Ethics Committee, New Zealand, #
CEN/07/03/014); or (iv) have been published previously (33).
(Figure 2A). This is understood to mean a follicle has
luteinized but not ruptured. This threshold can be used
as a tool for identifying the optimum times for an
ultrasound investigation and is an area requiring further
research.
ii Deficient luteal phase cycles show an E1G peak
followed by an increase in the PdG excretion rates
that exceed 9 µmol/24 h, but do not reach 13.5 µmol/24 h
(Figure 2B).
iii Short luteal phase cycles show an E1G peak before the
rise in the PdG excretion rate which may exceed 13.5
µmol/24 h, but the luteal phase length is 10 days or less
(Figure 2C).
D) Conceptual cycles are like fertile, non-conceptual cycles in
that the PdG excretion rates exceed 13.5 µmol/24 h within
6 days of the E1G peak, but the PdG excretion rates continue
to rise past 17 days (Figure 2D) and do not fall again until the
pregnancy is over.
It is especially important for any woman monitoring her own
fertility to know which of the cycle types in the continuum can be
followed by a fertile ovulation without an intervening menstrual
bleed [for an example see Figure 9 in Brown (1)]. The PdG
excretion rate is the key hormonal parameter that can be used
to determine what might follow. A PdG excretion rate in excess
of 9 µmol/24 h is usually followed by a normal menstrual bleed
up to 17 days later. After that any cycle type from the continuum
can follow in the subsequent cycle. However, if the PdG excretion
rates do not reach 7µmol/24 h, there are manymore possibilities.
For example, a completely anovular period (Figure 1B) may be
followed, without an intervening bleed, by a normal ovulatory
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FIGURE 2 | Patterns of PdG production and deficient cycle types. The PdG thresholds 7, 9, and 13.5 µmol/24 h are shown as broken horizontal lines. The vertical line
is the day of the LH peak. (A) A profile of a cycle with a luteinized unruptured follicle where the E1G excretion rates (◦) fluctuate and the PdG excretion rates (•) exceed
7 µmol/24 h, but not 9 µmol/24 h. (B) A profile of a cycle with a deficient luteal phase where the E1G excretion rates fluctuate and the PdG excretion rates exceed 9
µmol/24 h, but not 13.5 µmol/24 h. (C). A profile of a cycle with a short and deficient luteal phase. The E1G excretion rates fluctuate and there is an early E1G peak
on day 14. The luteal phase was 9 days counted from the peak E1G excretion rate day (day 20) to the day before the next bleed making it a short luteal phase and it
was also a deficient luteal phase as defined in (B) where the PdG excretion rates exceed 9 µmol/24 h, but not 13.5 µmol/24 h. (D) A pregnancy cycle with a classical
single E1G rate peak profile in the follicular phase and in which the PdG excretion rates exceed all the thresholds, but the rate has not decreased after 17 days from
the E1G peak day.
cycle (Figure 1A) or by any of the other possibilities of the
continuum. Such a completely anovular period does not help a
woman monitoring her own cycle to predict what will follow,
so continued vigilance is needed, and she should continue to
monitor her cycle. On the other hand, (i) raised estrogen levels
followed by a fall, indicating atresia of a developing follicle, can
be followed by a withdrawal bleed (Figure 1C), and (ii) raised
estrogens (Figure 1D) may result in a breakthrough bleed if the
levels are elevated for many days.
URINARY EXCRETION RATES VS.
CONCENTRATIONS
To take advantage of the continuum inmonitoring the menstrual
cycle it is essential that a very simple point is clear: the data must
be reliable and quantitative. There is a tendency to believe that
any method that yields a number is quantitative. However, just
getting a number is not helpful; the numbers must bemeaningful,
accurate and precise and of the right sort, especially when
considering the first rise in E1G levels to mark the beginning
of the fertile window (34) and the PdG (and Pd) thresholds. It
also needs to be stressed that the measurement is meaningful and
reliable only if it is an excretion rate, that is in units of time e.g.
µmol/24 h. The concentration of urinary PdG (or Pd) in µmol/L
is physiologically meaningless because differences in the volume
of the urine sample will affect the concentration profoundly
(35) and they cannot be anticipated. Just drinking more or less
will affect the PdG concentration, but it will not affect the PdG
excretion rate.
One way of thinking of this is to consider that the estradiol
secreted by the follicle is analogous to the production of widgets
by a factory: it makes sense to express the output of the factory
as widgets made per day, but it is less reasonable to express it
as widgets per volume of the boxes in which they are packed.
In the latter case the apparent productivity of the factory would
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change (downwards) if widgets were suddenly packed in bigger
boxes, but irrespective of the size of the boxes, the number of
widgets made per day is a value that the factory manager would
understand and find useful. The widget is analogous to a quantity
of urinary steroid and the volume of the boxes is analogous
to the volume of urine passed when a sample is obtained for
testing. The production of ovarian estradiol and progesterone
and their subsequent metabolism and excretion are all dynamic
processes: they change with time. Excretion rates are amounts per
time, whereas concentrations are amounts per volume and the
hormone output of the ovary is kinetically related to the former;
the concentration is an unreliable approximation.
The original chemical methods of Brown and his
contemporaries were all based on complete 24-h urine sample
collections, so that variations in the volume of urine excreted
were not a factor and the daily variation did not degrade the
information being collected. This applies particularly to the PdG
assays on which the thresholds used to define the cycle types
are based. Pregnanediol glucuronide (or its hydrolysis product,
Pd) is the major metabolite of ovarian progesterone. Although
there are variations between women, all women produce PdG
as their major metabolite and it has proved possible to establish
thresholds for Pd and PdG (36). This may not be possible for
the urinary metabolites of estradiol as it has long been known
that there are considerable variations between women in the
production of urinary estradiol, estrone, and estriol glucuronides,
and in the ratios in which they are produced (37, 38). For this
reason, we specify no E1G thresholds, although some have tried
(39). However, a significant increase from baseline in the E1G
excretion rate can be used as a marker for the beginning of the
fertile window (40).
While giving the excretion rate accurately, 24-h urine
collections are not suitable for daily monitoring of individuals in
the clinic or at home. Two main approaches have been used to
avoid 24 h collections.
The first, proposed by theWorld Health Organisation (WHO)
in the 1980s (41), is to ignore the fluctuations in the volume
of urine and assume that an overnight, or early morning, urine
collection is approximately constant in volume. Though an
overnight collection may be more constant than a day time
sample, they are still highly variable. Equally concerning is the
fact that the distributions of overnight void volumes and urine
production rates are positively skewed from which it can be
inferred that extreme values are more likely than would be
expected were the distribution normal.
The second approach to avoid a 24-h urine collection is to use
a sample of at least 3 h duration and then dilute the urine samples
to a constant urine production rate which eliminates the effect
of fluctuations in void volume (42). We have shown (42) that
diluting all urine samples to 150 mL/h before analysis (and then
expressing the output as the equivalent µmol PdG/24 h or nmol
E1G/24 h) gives the same excretion rates as those obtained with
24 h collections within the experimental errors of both methods
(43). There will always be uncertainty about the significance of
any measurement of urinary analyte concentration and only the
second approach gives the excretion rate of the metabolite.
In an individual, the serum estradiol concentration is usually
proportional to the urinary excretion rate of estrone glucuronide
(E1G) (38, 44–47). The latter is the product of the urinary
concentration of E1G and the urine production rate (in mL/h)
and we have shown that it is almost as important to measure the
urine production rate as it is to measure the E1G concentration
itself. It is essential that fluctuations in urine production rate
are taken into account if urinary glucuronides are to be used
to monitor the menstrual cycle accurately at home. This is
particularly important in the delineation of the limits of the fertile
window.
Urinary excretion rates are rarely used in monitoring fertility
(1, 36, 37, 48, 49). More often data are reported as urinary
analyte concentration normalized to either urinary creatinine
concentration or the specific gravity of the urine (50). Recently,
there have been several reports based only on urinary analyte
concentrations (39, 51–59). While it is likely that creatinine
corrected concentrations are less reliable than excretion rates
(60, 61), we believe that this is a much better approach than
merely relying on the concentration. There are, however, two
practical difficulties with creatinine correction which remain.
First, a creatinine assay suitable for use by a woman monitoring
PdG and E1G in her own home is required in addition to
the steroid assays (and the creatinine assay has to be of the
same quality as those for PdG and E1G). Second, the values
of creatinine-corrected PdG concentration corresponding to the
PdG thresholds on which the continuum-based interpretation
of the menstrual cycle relies have to be re-established using the
alternative combined PdG-creatinine assay system (62).
THE OVARIAN MONITOR PDG ASSAYS
AND BEYOND
We have developed several PdG assays with the potential for
home use. Of these, the Ovarian Monitor has allowed women to
understand their reproductive lives using the continuum (63) and
to identify accurately the precise end of their fertile window (36).
Extensive use was made of it for this purpose with home testing
in Victoria, Australia, in the 1990s (63). The details of what has
to be achieved to develop a suitable assay for PdG are given by
Binnie et al. (64). Essentially, the assay must give quantitative and
accurate excretion rates for a population of women, these must
correlate well with the reference chemical Pd assay on 24-h urine
collections (12) and give normal ranges which superimpose on
those given in Brown (1). This has been demonstrated for the
Ovarian Monitor PdG assay (34). The excretion rates of PdG,
measured using the Ovarian Monitor, and Pd, measured using
the reference chemical assay, are linearly related [PdG = 3.8 ×
Pd + 1.0 µmol/24 h, r = 0.95, n = 227 (65)], and the Ovarian
Monitor gives the same excretion rates for PdG (1, 65) as the
Pd reference assay after conversion of the Pd reference data
from mg/24 h to µmol/24 h. For these reasons we now use the
Ovarian Monitor PdG assay as our reference PdG assay because
the original Pd assay is not currently available. The PdG enzyme
linked immunosorbent assay gives the same excretion rate data
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FIGURE 3 | (A) PdG standard curve using the MICT superparamagnetic particle assay. The Y axis is the ratio of the magnetic intensity of the particles bound to the
test line divided by that of the control particles bound at the control line on the strips. Each point represents the mean (error bars ± SD) of 12 replicates (2 readers, 6
replicates each reader). (B–D) Comparison of menstrual cycle profiles from three women using paired serum progesterone concentration and urinary PdG excretion
rates. The serum values were obtained using a standard pathology progesterone assay of samples and the urine values were obtained using urine sample collected
on the same day diluted to 150 mL/h using the MICT superparamagnetic particle assay and the standard curve in (A). For subject B, the urines were all overnight
urine collections and the bloods were all collected later between 10:45 a.m.−1:10 p.m. For subject (C), all the urines were overnight collections and the bloods were
all collected later between 9 a.m. and 2:20 p.m. For subject (D), the urines were a mix of overnight and day time urines, but the bloods were all collected later
between 9:30 a.m. and 3:50 p.m.
as the Ovarian Monitor and thus provides a secondary reference
PdG assay (64).
Recently we have tested a new superparamagnetic particle
assay for PdG using the criteria given above. This method
has been validated against the Ovarian Monitor PdG assay
and also by comparison of the urinary PdG excretion rates
for menstrual cycle samples with the corresponding serum
progesterone levels determined in a pathology laboratory. When
correlating methods, it is important to be aware of the lowest
level of quantitation (LLOQ) of the different methods, and
correlate only those values within the working ranges of the
assays being compared. The new superparamagnetic particle
assay we used here (Figures 1B, 3A–D, 4A,B) employs magnetic
immunochemical test (MICT) technology (66). This is based on
the measurement of the magnetic field of paramagnetic beads
bound in a lateral flow immunoassay. The advantage is that
sensitivity of the detector yields both a very low LLOQ and a
very substantial working range.We have used superparamagnetic
particle assays for both E1G and PdG. Both assays outperform
the corresponding serum pathology laboratory assays in that
they measure changes in excretion rate for cycle days for
which the serum concentrations appear to be at (or below)
the LLOQ of the assay. The standard curve for the PdG assay
is shown in Figure 3A which confirms its very high precision
and remarkable working range. The coefficient of variation for
repeated determinations of the excretion rates on the standard
curve was <5% (average 3.5%). This high precision is important
as in general the coefficient of variation of the excretion rates
derived from the standard curve is approximately double the
coefficient of variation of the raw data. In the case of the MICT
assays, the parameter is the ratio of magnetic reading of the test
and control lines (67).
The OvarianMonitor PdG assays were designed specifically to
measure the key changes in themenstrual cycle (65) and thismust
be taken into account in inter-assay comparisons. The reactions
of the OvarianMonitor PdG assays are carried out in a single tube
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FIGURE 4 | (A) Correlation of the PdG values obtained with the MICT PdG assay vs. the excretion rates obtained for the same urine samples with the Ovarian Monitor
PdG assay. The upper and lower limits of quantitation were calculated for both assays and only data that were within the range for each assay were correlated. The
line shown was obtained by Deming regression. (B) The Bland-Altman plot of the data is shown where the difference between the two assays (MICT—OM) is
calculated and plotted against the mean of the two values. (68).
using only mildly diluted urine samples (to 150 mL/h of urine
collection, which usually corresponds to a dilution by a factor of
between 3 and 8). This has two important consequences. First,
as with many immunoassays, there is a matrix effect that can
lead to spurious results if not taken into account (69). This is
minimized in the Ovarian Monitor assays by a pre-incubation
step (43, 65). The matrix effect can be diluted out to some
extent, but large dilutions of the sample are not possible for
home assays of ovarian steroids. Second, the working range
of the Ovarian Monitor PdG assay is restricted which means
that higher excretion rates can only be measured accurately
with further dilution of the samples. Despite these difficulties,
there is good agreement between the Ovarian Monitor excretion
rates for PdG and the corresponding superparamagnetic assay
PdG excretion rates as shown in Figure 4A. There is little
bias and no systematic variation in the differences between the
two assays (Figure 4B). The relationship between the MICT
and Ovarian Monitor (OM) assays is MICT = (1.1 ± 0.1) ×
OM − (0.46 ± 0.41) µmol/24 h (± 1.96SE) which shows that
the assays give the same excretion rates within experimental
uncertainty. This implies that the same PdG thresholds (34)
might be used with the new superparamagnetic particle assays.
The urinary PdG MICT and serum progesterone profiles for the
cycles shown in Figures 3B–D also overlap well. However, the
working range of the standard pathology laboratory progesterone
assay does not cover the very lowest progesterone concentrations
(the LLOQ was 0.5 nmol/L), whereas the working range of the
superparamagnetic particle PdG urinary assay does cover the
lowest PdG excretion rates. For this reason, the cycle data in
Figures 3B–D can only be compared on those days when the
serum progesterone concentration exceeds about 0.5 nmol/L.
During this period, it is clear that there may be a slight delay
between the serum concentration and the urinary excretion
rate, consistent with the time difference between the midpoint
of the overnight urine collection (≈3 AM) and the day time
blood collection (≈ 9 AM), and also the time required for
progesterone to be metabolized to PdG and excreted. If this is
considered, the agreement between the profiles is outstanding
and further validates a new superparamagnetic particle urinary
PdG assay.
Another important consideration is the antibody. The
antibody used in the assays matters and always should be
thoroughly characterized (70). In an immunoassay, a signal will
almost always be obtained, but great care has to be taken to
show that it can be converted into a number which measures the
actual amount of analyte present in the sample. No antibody is
completely specific for a particular analyte in the presence of high
concentrations of a structurally related contaminant. The new
PdG assays using urine samples diluted according to time give
excretion rates entirely comparable with the Pd chemical assay
which is the foundation of the continuum.
THE CONTINUUM AND CYCLE
AVERAGING
The ovarian steroid profiles of individual cycles have a low
signal:noise ratio if the data are not corrected for urine
production rate. The predominant response to this in the
literature has been to align all cycles relative to a mid-cycle
marker, such as the LH peak or the ultrasound derived day
of ovulation, and then to calculate daily averages of the data
from many cycles. Inevitably, this gives smoother profiles, but it
conceals information that is important to the management of a
woman’s fertility (71).
We are focussed on devices that enable a woman to (i)
monitor her own fertility in her own home each day and
(ii) integrate the hormone excretion rates and her natural
signs of fertility. In particular, we want to define the limits
of the fertile window with accuracy and hence to reduce the
potential period of abstinence for pregnancy avoidance to the
true minimum. At present, a woman has access only to her
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own cycles and it is probably pragmatic to assume that she
has access only to her current cycle. Even if average cycles
are available, averages of cycle populations or even a woman’s
own past cycles are not helpful to an individual dealing with
her current cycle. Simply averaging a large number of cycles
is meaningless unless they are all the same type of cycle, a
problem that the continuum could be helpful in resolving.
The only useful aspect of averaged cycles for a woman is the
uncertainty envelope within which she might expect her profile
to lie, in at least some circumstances, but this still doesn’t give
her any absolute information about her current cycle. Each cycle
reflects a woman’s own unique physiological, psychological and
environmental circumstances which do not remain static, so her
cycle can easily change frommonth tomonth. A woman who had
an “average” cycle 1 month might well have quite a different cycle
the next.
The E1G and PdG excretion rate profiles of an individual
provide reliable data which she can use to locate her changing
position on the continuum, as well as understand her current
cycle as it proceeds. Eventually, her personal interpretationmight
be enhanced, as suggested previously (35) by integration of other
data and data sharing. However, this has to be subject to ethical
approval and some semblance of agreement as to some details
of measurement, such as correction of urinary measurements for
fluctuations in urine production rate (67).
While considering a single cycle may be irrelevant in
population research, it is the only case of importance for a
woman. Given this, and especially the logical inconsistencies
inherent in most cycle averages, we have always analyzed
individual cycles using excretion rates. The analysis of over a
million estrogen and pregnanediol excretion rates formed the
basis of Brown’s continuum (1). However, the reluctance to
correct for urine production rate has been one of the main
impediments to the recognition of the continuum. Women,
couples and clinicians require a guide to the intricacies of
the menstrual cycle that does not rely on complex rules and
minimizes excess abstinence and possible misdiagnoses. The
continuum provides such a guide.
With current technological advances, we expect remote cycle
monitoring through a device such as a smart phone will become
the new reality. This raises many issues, some of which we
have considered elsewhere (35). When this point is reached
the software might well have access to more of a woman’s
own data and more sophisticated analyses may well be helpful.
Nevertheless, because of the range of cycle variations even in
an individual it is unlikely that this will be a simple statistical
problem. An example of the variation that can be observed
is illustrated clearly in section What can you tell using the
continuum?
WHAT CAN YOU TELL USING THE
CONTINUUM?
Based on the cycle types we have described (section
Characterizing the continuum), the PdG and E1G excretion rates
enable women to identify the type of their cycle and its place in
the continuum and, to some extent, the likely sequelae (1). It is
also possible to identify the start and end of the fertile period
accurately which gives a shorter fertile window than any other
method (34), and thus, depending on the woman’s intentions
and the nature of her cycle, can assist her to conceive or avoid
pregnancy. Daily testing is not necessary as an understanding
of the continuum cycle types and their possible sequelae can
be used to guide a woman as to the appropriate days for
testing. The continuum is also helpful to the many women
who have difficulty conceiving, and to their clinicians, because
it provides (i) insight into the nature of the problem and its
persistence, (ii) a means of assessing whether intervention, such
as treatment with clomiphene, is warranted, and (iii) could be
used to assist in interpreting events in infertility treatments, for
example in clearly identifying the most appropriate day for an
ultrasound scan or in helping titrate the dose of gonadotrophins
(15).
One example of the continuum as a guide to the sequence
of measurements women should make is the WHO sponsored
trial of the Ovarian Monitor (72). In that study each woman
contributed 6 cycles of data obtained at home with the Ovarian
Monitor. During the first two cycles, women measured their E1G
and PdG excretion rates daily (32, 34, 72, 73). For the following
4 cycles they monitored their daily E1G excretion rates until a
mid-cycle E1G peak was identified and then tested for PdG until
the value of 7 µmol PdG/24 h. At this point most, but not all,
women stopped collecting data in that cycle (a PdG excretion
rate of 7 µmol/24 h indicates the end of the current fertile period
and ultrasound measurements of the endometrium at this level
confirm that bleeding will follow). The 75 women in the trial
contributed 357 cycles in total and 222 of these were cycles 3–
6. As the protocol did not require that they continue testing once
it had been established that the fertile period had ended, it was
possible to establish the cycle type for only 109 cycles. In these
109 cycles, when the PdG excretion rates did not rise rapidly
or did not exceed 9 µmol/24 h, the women often continued the
measurements long enough into their luteal phases for the cycle
type to be identified.
An example of a woman exhibiting a range of different cycle
types is shown in Figure 5A. For this woman, the first two
cycles were “normal” as the PdG excretion rates exceeded 13.5
µmol/24 h within 6 days of the E1G peak (1) and she had very
high peak day E1G excretion rates - ideally, she should have done
an extra dilution of these days for cycles 1 and 2 and repeated
them as they were off scale and gave her a truncated E1G peak.
For her third cycle, although the E1G excretion rates were again
high, the PdG excretion rates suggested a deficient luteal phase.
In her fourth cycle, the woman estimated the start of her fertile
period on the basis of her mucus symptom as cycle day 7, the
mucus peak day as day 13 and the BBT shift day as day 16
(Figure 5B). The E1G excretion rate declined over the first few
days of the cycle and the first rise in E1G excretion rate, the start
of the potentially fertile phase, was identified by the woman as
day 7 (ignoring the spike on day 5). This agrees with the mucus
symptom she reported, but the day of E1G peak excretion was
day 11 compared with the reported mucus peak day of 13. The
last day of fertility, day 14, was the day before the PdG excretion
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FIGURE 5 | The eight consecutive cycles obtained by a single participant in the WHO study showing her personal continuum (A,B) a detailed view of cycle 4 shown in
(A). The PdG thresholds 7, 9, and 13.5 µmol/24 h are shown as broken horizontal lines. Further discussion is given in the text.
rate first exceeded 7 µmol/24 h and the fertile window was 8 days
(days 7–14). However, as the PdG excretion rate did not exceed 9
µmol/24 h the cycle was probably a LUF. The BBT shift day (last
day of fertility= BBT+ 2) and the cervical mucus symptom (last
day of fertility = mucus peak day + 3) indicated to the woman
that her infertile period could be assumed to have begun on day
19 and 17, respectively.
The E1G and PdG excretion rate data assisted this woman in
at least four ways. First, the period of abstinence was reduced
from 12 days (days 7–18), based on the most conservative
symptothermal end of potential fertility marker, to 8 days.
Second, the cycle was identified as probably involving a luteinized
unruptured follicle since the PdG excretion rate exceeded 7
µmol/24 h, but did not exceed 9 µmol/24 h. We remind the
reader that this hormonal definition of a LUF differs from
that based on observation using ultrasound. Third, the analysis
had greater certainty than would have been the case based
on other measures, allowing her to live her life with fewer
constraints. Fourth and more importantly, she would know from
the continuum that this LUF would not be followed by another
follicle without an intervening bleed. In practice, she did bleed
again on cycle day 25 without any further follicle developing. In
the next cycle, cycle 5 she bled heavily for the first 3 days and then
had 2 days of spotting including blood stained mucus on day 6.
She correctly identified this as the start of potential fertility in
this cycle since the protocol required the participants to identify
this day by the first day of mucus. In agreement with her mucus
symptoms, the E1G excretion rate also rose on cycle day 6. She
did not continue her PdG testing long enough into the luteal
phase of this cycle to determine the cycle type. However, the
next cycle she monitored, cycle 6, had a short luteal phase. She
also monitored two more successive cycles not required by the
protocol. The seventh cycle was probably normal, but insufficient
PdG data were collected to be certain, and this was also the case
for the eighth cycle. The E1G excretion rates were considerably
lower for the last five cycles than for the first two. However, the
last two cycles had greater E1G excretion rates than cycles five
and six, perhaps indicating a return to more “normal” cycling.
It is notable, but not especially remarkable, that in only
eight consecutive cycles this woman exhibited four different
cycle types, and these were clearly identified using. the
continuum as (in order): “normal;” “normal;” deficient luteal
phase; LUF; undetermined; a short luteal phase, undetermined
and undetermined. The three undetermined cycles were
undetermined only because measurement of luteal phase PdG
excretion rates was stopped too soon. By all standard criteria,
this woman would be considered to be cycling “normally” (34),
but her very different cycles illustrate one of the problems of
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averaging the cycles of such “normally” cycling women. If the
various cycle types are not distinguished, it is inappropriate to
average them, and the corollary is that means and standard
deviations can be highly misleading if based on samples that are
not comparable.
CONCLUSIONS
Our purpose has been to provide clinicians and others with
references and discussion of the key factors involved in the use
of the continuum by individual women who hope to avoid or
achieve conception. We understand that the information in this
review is of little use to women unless they have access to a
device which allows them to determine their results at home. Of
course, if laboratories correct for urine volume by time dilution
and carry out the tests described here, standard validated assays
for E1G and PdG should yield data that can be interpreted using
the continuum and the PdG thresholds. We would be happy
to confirm this with our reference Ovarian Monitor PdG assay.
Women deserve a solution which they can rely upon.
The Monitor assay became moribund with the death of
Professor James Brown. However, we have now recovered the
production of the monitors and tubes at least for research use,
and we are also producing prototypes for new, rapid, accurate
assays for PdG for clinic based, and home use. In parallel, we
are investigating procedures to determine the production rate
of a urine sample without any need for information on the
time or volume of the collection which will make urine the
medium of choice. At present, we do not really contemplate the
possibility of serum assays because of the invasiveness and cost
of sample collection and the difficulties of sample collection in
the home environment. Nor do we do seriously contemplate the
use of any other bodily fluids. We believe that our new assays,
combined with the newmethod of determining the urine volume
production rate, will allow women to navigate their personal path
through the continuum with ease.
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